该研究的目的是通过系统回顾和荟萃分析来确定异质性组分在妇科肉瘤中的组织学存在是否作为预后因素。在PubMed、Web of Science和Embase中搜索了相关出版物。包括评估人类卵巢或子宫肉瘤的肉瘤组分对生存效果的研究在内。两位作者根据符合条件的参考文献独立进行了审核，提取了包括原发肿瘤部位、生存结局、生存结局类型和每种肉瘤分化比例在内的数据。使用Newcastle-Ottawa量表评估了每个合格研究的质量。采用随机效应模型进行荟萃分析，以估计带有或不带有异质性组分的肉瘤的生存结局的风险比（HR）和95%置信区间（CI）。共鉴定了8项涉及1,594名患者的研究。异质性组分的总体比例为43.3%。异质性组分的存在与整体生存率较差有关（HR=1.81，95％CI=1.15-2.85），但与复发无关生存和无病生存的荟萃分析（HR=1.79，95％CI=0.85-3.77）。去除多元回归分析研究、早期研究、卵巢肿瘤研究或有大量患者样本的研究并不影响异质性组分与整体生存之间的统计学差异。妇科肉瘤在组织学上是由上皮和间叶组分组成的二相性肿瘤。我们的研究强调，考虑到所有阶段的情况下，病理学评估异质性组分是妇科肉瘤的预后因素。PROSPERO标识符：CRD42022298871。© 2023年。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

The aim of this study is to determine the histologic presence of heterologous component as a prognostic factor in gynecologic carcinosarcoma through a systematic review and meta-analysis.PubMed, Web of Science, and Embase were searched for publications. Studies that evaluated survival effect of sarcomatous component based on histology in human ovarian or uterine carcinosarcoma were included. Two authors independently reviewed the references based on eligibility criteria and extracted the data including primary tumor site, survival outcome, type of survival outcome, and proportion of each sarcomatous differentiation. The quality of each eligible study was assessed with Newcastle-Ottawa scale. Meta-analysis was conducted using a random-effects model to estimate hazard ratio (HR) and 95% confidence intervals (CIs) of survival outcome for carcinosarcoma with or without heterologous component.Eight studies including 1,594 patients were identified. Overall proportion of carcinosarcoma with heterologous component was 43.3%. Presence of heterologous component was associated with worse overall survival (HR=1.81; 95% CI=1.15-2.85) but not with pooled recurrence-free survival and disease-free survival (HR=1.79; 95% CI=0.85-3.77). Removing multivariate analysis studies, early-stage studies, ovarian tumor study, or studies with large number of patient samples did not affect the significance between heterologous component and overall survival.Gynecologic carcinosarcoma is histologically a biphasic tumor which comprise of epithelial and mesenchymal components. Our study emphasizes pathologic evaluation of heterologous component as a prognostic factor in gynecologic carcinosarcoma when all stages were considered.PROSPERO Identifier: CRD42022298871.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.